By Dean Seal
Shares of Septerna sank to their lowest level yet after the company said it would end the phase 1 clinical trial for SEP-786 as a treatment for hypoparathyroidism.
The stock fell 68% to a low of $4.17 in early trading. The stock just hit the market last fall.
The clinical-stage biotech company said Tuesday that it would stop the trial based on two unanticipated and severe events that didn't cause liver injury or other serious adverse effects, but prompted the discontinuation of dosing for both study participants.
The company said it would initiate non-clinical studies to investigate what was observed during phase 1.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
February 18, 2025 10:26 ET (15:26 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。